drugset / Trial / NCT01097460

MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer

NCT01097460

Phase 1 Completed 16 enrolled Merrimack Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label Phase 1 trial of MM-111 in combination with Herceptin.

Timeline

Start
2010-04
Primary completion
2013-07
Completion
2013-07

Drugs

EvaluationDrugModalityDoseRoute
Subject MM-111 Unknown Intravenous
Subject Trastuzumab Monoclonal antibody Intravenous

Indications